Cargando…

Patient Preference Distribution for Use of Statin Therapy

IMPORTANCE: Thresholds for initiating statin therapy should be informed by patients’ preferences. OBJECTIVE: To define the preference distribution for statin therapy across the spectrum of cardiovascular disease (CVD) risk after participants were informed about the benefits and harms of statin thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Brodney, Suzanne, Valentine, K. D., Sepucha, Karen, Fowler, Floyd J., Barry, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961307/
https://www.ncbi.nlm.nih.gov/pubmed/33720368
http://dx.doi.org/10.1001/jamanetworkopen.2021.0661
_version_ 1783665230501380096
author Brodney, Suzanne
Valentine, K. D.
Sepucha, Karen
Fowler, Floyd J.
Barry, Michael J.
author_facet Brodney, Suzanne
Valentine, K. D.
Sepucha, Karen
Fowler, Floyd J.
Barry, Michael J.
author_sort Brodney, Suzanne
collection PubMed
description IMPORTANCE: Thresholds for initiating statin therapy should be informed by patients’ preferences. OBJECTIVE: To define the preference distribution for statin therapy across the spectrum of cardiovascular disease (CVD) risk after participants were informed about the benefits and harms of statin therapy. DESIGN, SETTING, AND PARTICIPANTS: A cross-sectional survey was conducted from May 13 to June 2, 2020. Participants included 304 individuals aged 40 to 75 years drawn from a nonprobability opt-in panel who had not taken a statin or proprotein convertase subtilisin/kexin type 9 inhibitor in the past 3 years and knew the results of their total cholesterol, high-density lipoprotein cholesterol, and blood pressure measurements. EXPOSURES: Personalized 10-year CVD risk with and without statin therapy and potential harms of statins. MAIN OUTCOMES AND MEASURES: The primary outcome was self-reported preference for statin therapy. RESULTS: The 304 participants had a mean (SD) age of 54.8 (9.9) years; 152 were women (50.0%), 130 (42.8%) non-White, 50 (16.6%) had a high school degree or less education, and 153 (50.8%) reported never needing help reading health materials. When asked their preference for using statin therapy after reviewing their benefit and risk information, 45% of the participants reported they would definitely or probably choose statin therapy. As the risk increased, the proportion who would choose statin therapy generally increased (from 31.1% for a risk <5% to 82.6% for a risk >50%). The minimum risk threshold had to increase to 20% before 75% of respondents in that risk group would want statin therapy. For participants with a risk greater than 10%, the desire to use statin therapy decreased as participants’ health literacy, subjective numeracy, and knowledge scores increased. CONCLUSIONS AND RELEVANCE: In this study, preferences for statin therapy for primary prevention of CVD appeared to vary across the spectrum of 10-year cardiovascular risk, but they were relatively flat at intermediate levels of risk. This preference distribution suggests a broad risk range for shared decision-making.
format Online
Article
Text
id pubmed-7961307
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-79613072021-04-01 Patient Preference Distribution for Use of Statin Therapy Brodney, Suzanne Valentine, K. D. Sepucha, Karen Fowler, Floyd J. Barry, Michael J. JAMA Netw Open Original Investigation IMPORTANCE: Thresholds for initiating statin therapy should be informed by patients’ preferences. OBJECTIVE: To define the preference distribution for statin therapy across the spectrum of cardiovascular disease (CVD) risk after participants were informed about the benefits and harms of statin therapy. DESIGN, SETTING, AND PARTICIPANTS: A cross-sectional survey was conducted from May 13 to June 2, 2020. Participants included 304 individuals aged 40 to 75 years drawn from a nonprobability opt-in panel who had not taken a statin or proprotein convertase subtilisin/kexin type 9 inhibitor in the past 3 years and knew the results of their total cholesterol, high-density lipoprotein cholesterol, and blood pressure measurements. EXPOSURES: Personalized 10-year CVD risk with and without statin therapy and potential harms of statins. MAIN OUTCOMES AND MEASURES: The primary outcome was self-reported preference for statin therapy. RESULTS: The 304 participants had a mean (SD) age of 54.8 (9.9) years; 152 were women (50.0%), 130 (42.8%) non-White, 50 (16.6%) had a high school degree or less education, and 153 (50.8%) reported never needing help reading health materials. When asked their preference for using statin therapy after reviewing their benefit and risk information, 45% of the participants reported they would definitely or probably choose statin therapy. As the risk increased, the proportion who would choose statin therapy generally increased (from 31.1% for a risk <5% to 82.6% for a risk >50%). The minimum risk threshold had to increase to 20% before 75% of respondents in that risk group would want statin therapy. For participants with a risk greater than 10%, the desire to use statin therapy decreased as participants’ health literacy, subjective numeracy, and knowledge scores increased. CONCLUSIONS AND RELEVANCE: In this study, preferences for statin therapy for primary prevention of CVD appeared to vary across the spectrum of 10-year cardiovascular risk, but they were relatively flat at intermediate levels of risk. This preference distribution suggests a broad risk range for shared decision-making. American Medical Association 2021-03-15 /pmc/articles/PMC7961307/ /pubmed/33720368 http://dx.doi.org/10.1001/jamanetworkopen.2021.0661 Text en Copyright 2021 Brodney S et al. JAMA Network Open. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Original Investigation
Brodney, Suzanne
Valentine, K. D.
Sepucha, Karen
Fowler, Floyd J.
Barry, Michael J.
Patient Preference Distribution for Use of Statin Therapy
title Patient Preference Distribution for Use of Statin Therapy
title_full Patient Preference Distribution for Use of Statin Therapy
title_fullStr Patient Preference Distribution for Use of Statin Therapy
title_full_unstemmed Patient Preference Distribution for Use of Statin Therapy
title_short Patient Preference Distribution for Use of Statin Therapy
title_sort patient preference distribution for use of statin therapy
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961307/
https://www.ncbi.nlm.nih.gov/pubmed/33720368
http://dx.doi.org/10.1001/jamanetworkopen.2021.0661
work_keys_str_mv AT brodneysuzanne patientpreferencedistributionforuseofstatintherapy
AT valentinekd patientpreferencedistributionforuseofstatintherapy
AT sepuchakaren patientpreferencedistributionforuseofstatintherapy
AT fowlerfloydj patientpreferencedistributionforuseofstatintherapy
AT barrymichaelj patientpreferencedistributionforuseofstatintherapy